Susceptibilities of Candida Species to Amphotericin B and Fluconazole: The Emergence of Fluconazole Resistance in Candida tropicalis

Author(s): Yun-Liang Yang, PhD; Yong-An Ho, BSc; Hsiao-Hsu Cheng, BSc; Monto Ho, MD; Hsiu-Jung Lo, PhD

Source: Infection Control and Hospital Epidemiology, Vol. 25, No. 1 (January 2004), pp. 60-64

Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America

Stable URL: http://www.jstor.org/stable/10.1086/502294

susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis

Yun-Liang Yang, PhD; Yong-An Ho, BSc; Hsiao-Hsu Cheng, BSc; Monto Ho, MD; Hsiu-Jung Lo, PhD

ABSTRACT

OBJECTIVE: To determine the susceptibilities of Candida species isolated from Taiwan to amphotericin B and fluconazole.

DESIGN: Prospective surveillance study.

METHODS: Each hospital was asked to submit up to 10 C. albicans and non-albicans Candida species during the collection period, from April 15 to June 15, 1999. One isolate was accepted from each episode of infection. The broth microdilution method was used to determine susceptibilities to amphotericin B and fluconazole.

RESULTS: Only 3 of 632 isolates, one each of C. famata, C. krusei, and C. tropicalis, were resistant to amphotericin B. A total of 53 (8.4%) of 632 clinical yeast isolates, consisting of 4% C. albicans, 8% C. glabrata, 15% C. tropicalis, and 70% C. krusei, were resistant to fluconazole. In contrast, no C. parapsilosis isolate was resistant to fluconazole. Isolates from tertiary-care medical centers had higher rates of resistance to fluconazole than did those from regional and local hospitals (11.4% vs 6.6%). Isolates from different sources showed different levels of susceptibility to fluconazole. All of the isolates with the exception of C. tropicalis and C. krusei isolated from blood were susceptible to fluconazole. A pattern of co-resistance to both amphotericin B and fluconazole was observed.

CONCLUSIONS: Non-albicans Candida species had higher rates of resistance to fluconazole than did C. albicans (44 of 395 [11.2%] vs 9 of 237 [3.8%]; P = .002). The increasing rate of fluconazole resistance in C. tropicalis (15%) is important because C. tropicalis is one of the most commonly isolated non-albicans Candida species (Infect Control Hosp Epidemiol 2004;25:90-94).

In the past decade, nosocomial infections caused by yeast have increased significantly. In the United States, yeast infections rank as the fourth most common cause of nosocomial bloodstream infection.1,2 The prevalence of nosocomial candidemia increased 27-fold from 1981 through 1993 at a hospital in Taiwan.3,4 The dramatic increases in the prevalence of fungal infections are probably the result of alterations in immune status associated with the acquired immunodeficiency syndrome epidemic, cancer chemotherapy, organ and bone marrow transplantation,5 frequent broad-spectrum antibiotic therapy, and invasive hospital procedures.

Currently available antifungal drugs can have troublesome side effects, are ineffective against some fungi, and lead to the development of resistance. Antifungal drug resistance has become an important issue for a variety of fungal infections. Oropharyngeal candidiasis due to drug-resistant fungi is a major problem for patients infected with human immunodeficiency virus.6 One-third of patients with late-stage acquired immunodeficiency syndrome had drug-resistant strains of Candida albicans in their mouth in one report.7 The rate of invasive fungal infection among liver transplant patients in another study was 11% and 40% of the patients with systemic fungal infection died. Seventy-two percent of these deaths were attributed to the fungal infection.8

Candida species have varying degrees of susceptibility to common antifungal agents. C. inisitiae is relatively resistant to amphotericin B.9 C. krusei and C. glabrata are less susceptible to fluconazole than are other Candida species.10,11 Although C. tropicalis is less commonly isolated from clinical specimens than is C. albicans, it is one of the most common non-albicans Candida species12,13 and it is always associated with diseases.12,14 Among non-albicans Candida species, C. tropicalis is considerably clinically important because it develops fluconazole resistance rapidly.

Dr. Yang is from the Department of Biological Science and Technology, National Chiao Tung University, Hsinchu; and Drs. Monto Ho and Lo, Mr. Yong-An Ho, and Mr. Cheng are from the Division of Clinical Research, National Health Research Institutes, Taipei, Taiwan, Republic of China.

Address reprint requests to Hsiu-Jung Lo, PhD, Division of Clinical Research, National Health Research Institutes, 128, Yen-Chi-Yuan Road, Section 2, Taipei, 11529, Taiwan, Republic of China.

The authors thank Dr. Y.C. Chen for her helpful suggestions, and Bristol Myers Squibb and Pfizer for supplying the amphotericin B and fluconazole, respectively. They also thank the following 22 participating hospitals for providing the isolates and information related to the isolates: Chang Gung Memorial Hospital at Linkou, Chang Gung Memorial Hospital at Keelung, Hsin-Chu Hospital, Lo-Tung Poh Ai Hospital, St. Mary Hospital, Taipei Municipal Yang-Ming Hospital, Taipei Municipal Zen Ai Hospital, Tao-Yuan General Hospital, Taiwan Adventist Hospital, Koo Foundation Sun Yat-sen Cancer Center, Tri Service General Hospital, Kuan-Tien General Hospital, Veterans General Hospital-Taichung, Zen Ai General Hospital, Chi Mei Hospital, Kaohsiung Medical College Chung-Ho Memorial Hospital, Kaohsiung Military Hospital, Tainan Municipal Hospital, Veterans General Hospital-Kaohsiung, Buddhist Tzu-Chi General Hospital, Hua-Lien Hospital, and Mackay Memorial Hospital Taitung Branch.

This content downloaded from 140.113.38.11 on Sun, 27 Apr 2014 21:48:19 PM
All use subject to JSTOR Terms and Conditions
ly17 and the rate of resistance to fluconazole of clinical C. tropicalis isolates is increasing.18-21 We previously reported a national survey in Taiwan in which 22 hospitals contributed 660 clinical yeast isolates.22 The current study showed that the levels of susceptibility to fluconazole of Candida species were different among different species and also among the same species from different sources. Our data suggested that, in addition to C. krusei and C. glabrata, C. tropicalis should be on the list of yeast for which fluconazole resistance is common.

METHODS

Organisms and Medium

Yeast isolates were collected from 22 hospitals participating in Taiwan Surveillance of Antimicrobial Resistance of Yeasts (TSARY). Six were tertiary-care medical centers, 14 were regional hospitals, and 2 were local hospitals. Each hospital was asked to submit up to 10 C. albicans and 40 non-albicans Candida species during the collection period, from April 15 to June 15, 1999. One isolate was accepted from each episode of infection. Isolates were stored frozen at -70°C in bead-containing Microbank cryovials (PRO-LAB Diagnostics, Austin, TX). At the end of the collection period, isolates were kept frozen and transported to the National Health Research Institutes laboratory within 24 hours. The isolates were first subcultured on Sabouraud dextrose agar (BBL Becton Dickinson, Cockeysville, MD) to check for purity and identification. Pure isolates were labeled and stored in vials containing 50% glycerol at -70°C for further analysis.

Antifungal Susceptibility Testing

The minimum inhibitory concentration (MIC) to amphotericin B or fluconazole of each yeast was determined by in vitro antifungal susceptibility testing according to guidelines published by the National Committee for Clinical Laboratory Standards.23 The powder of RPMI medium 1640 was provided by Gibco BRL (Cat.# 31800-
Several strains from the American Type Culture Collection were used as standard controls. The final growth of each isolate was measured by a Spectra MAX Plus (Molecular Devices Corp., Sunnyvale, CA) after 48 hours of incubation at 35°C. The MIC of each isolate was measured at least twice. When the results of two susceptibility tests differed by more than onefold dilution, they were retested. MICs of some isolates were measured by Etest (AB Biodisk, Solna, Sweden) to confirm our microdilution results.

The interpretation of MICs was according to the guidelines of the National Committee for Clinical Laboratory Standards. The MICs to amphotericin B and fluconazole were defined as those that could reduce the turbidity of cells by greater than 95% and 50%, respectively. Isolates with a MIC of 2 µg/mL or greater were considered to be resistant to amphotericin B. Isolates with a MIC of 1 µg/mL or less were considered to be susceptible. Isolates with a MIC of 64 µg/mL or more were susceptible-dose dependent. The MICs of 50% and 90% of the total population were defined as MIC\textsubscript{50} and MIC\textsubscript{90}, respectively.

**Table 3**

<table>
<thead>
<tr>
<th>Source</th>
<th>C. albicans</th>
<th>C. tropicalis</th>
<th>C. glabrata</th>
<th>C. parapsilosis</th>
<th>C. krusei</th>
<th>Others</th>
<th>Subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>100 (15) *</td>
<td>58.4 (7)</td>
<td>87.5 (7)</td>
<td>100 (13)</td>
<td>0</td>
<td>100 (2)</td>
<td>86.5 (44)</td>
</tr>
<tr>
<td>SDD</td>
<td>0</td>
<td>83.1 (1)</td>
<td>12.5 (1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3.9 (2)</td>
</tr>
<tr>
<td>R</td>
<td>1</td>
<td>33.3 (4)</td>
<td>0</td>
<td>0</td>
<td>100 (1)</td>
<td>0</td>
<td>9.8 (5)</td>
</tr>
<tr>
<td><strong>Sputum</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>90.2 (74)</td>
<td>81.4 (35)</td>
<td>55 (11)</td>
<td>100 (2)</td>
<td>0</td>
<td>66.7 (2)</td>
<td>82.2 (125)</td>
</tr>
<tr>
<td>SDD</td>
<td>3.7 (3)</td>
<td>4.7 (2)</td>
<td>30 (8)</td>
<td>0</td>
<td>0</td>
<td>33.3 (1)</td>
<td>7.9 (12)</td>
</tr>
<tr>
<td>R</td>
<td>6.1 (5)</td>
<td>13.9 (6)</td>
<td>15 (3)</td>
<td>0</td>
<td>100 (1)</td>
<td>0</td>
<td>9.9 (15)</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>94.9 (75)</td>
<td>75.3 (55)</td>
<td>80.2 (85)</td>
<td>85.7 (6)</td>
<td>0</td>
<td>100 (3)</td>
<td>82 (224)</td>
</tr>
<tr>
<td>SDD</td>
<td>3.8 (3)</td>
<td>6.9 (5)</td>
<td>12.3 (13)</td>
<td>14.3 (1)</td>
<td>40 (2)</td>
<td>0</td>
<td>8.8 (24)</td>
</tr>
<tr>
<td>R</td>
<td>1.3 (1)</td>
<td>17.8 (13)</td>
<td>7.5 (8)</td>
<td>0</td>
<td>60 (3)</td>
<td>0</td>
<td>9.2 (25)</td>
</tr>
<tr>
<td><strong>Wound</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>90 (18)</td>
<td>92.3 (12)</td>
<td>100 (4)</td>
<td>100 (11)</td>
<td>0</td>
<td>0</td>
<td>91.8 (45)</td>
</tr>
<tr>
<td>SDD</td>
<td>0</td>
<td>7.7 (1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100 (1)</td>
<td>4.1 (2)</td>
</tr>
<tr>
<td>R</td>
<td>10 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4.1 (2)</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>95.2 (39)</td>
<td>91 (20)</td>
<td>77.8 (14)</td>
<td>100 (17)</td>
<td>0</td>
<td>100 (6)</td>
<td>89.7 (96)</td>
</tr>
<tr>
<td>SDD</td>
<td>2.4 (1)</td>
<td>4.5 (1)</td>
<td>11.1 (2)</td>
<td>0</td>
<td>33.3 (1)</td>
<td>0</td>
<td>4.7 (5)</td>
</tr>
<tr>
<td>R</td>
<td>2.4 (1)</td>
<td>4.5 (1)</td>
<td>11.1 (2)</td>
<td>0</td>
<td>66.7 (2)</td>
<td>0</td>
<td>5.6 (6)</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>93.2 (221)</td>
<td>79.2 (129)</td>
<td>77.6 (121)</td>
<td>98 (50)</td>
<td>0</td>
<td>86.7 (13)</td>
<td>84.5 (534)</td>
</tr>
<tr>
<td>SDD</td>
<td>3 (7)</td>
<td>6.1 (10)</td>
<td>14.1 (22)</td>
<td>2 (1)</td>
<td>30 (3)</td>
<td>13.3 (2)</td>
<td>7.1 (45)</td>
</tr>
<tr>
<td>R</td>
<td>3.8 (9)</td>
<td>14.7 (24)</td>
<td>8.3 (13)</td>
<td>0</td>
<td>70 (7)</td>
<td>0</td>
<td>8.4 (53)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>37.5 (237)</td>
<td>25.8 (163)</td>
<td>24.7 (156)</td>
<td>8.1 (51)</td>
<td>1.6 (10)</td>
<td>2.3 (15)</td>
<td>100 (632)</td>
</tr>
</tbody>
</table>

S = susceptible; SDD = susceptible-dose dependent; R = resistant.
\*Percentage (number of isolates).

**Database and Analysis**

In addition to identifying isolates, contributing hospitals also provided the following information about each isolate: location and type of hospital, genus and species as identified by each hospital, source (urine, sputum, blood, wound, and 48 other sources), and procedures for identification. An analysis was performed using Epi-Info software (version 6.04; Centers for Disease Control and Prevention, Atlanta, GA). The significance of differences in proportions was determined by the chi-square test with Yate's correction.

**RESULTS**

**Candida Species From Different Sources**

A total of 632 isolates were analyzed for their susceptibilities to amphotericin B and fluconazole. *C. albicans* was the most common species (37.5% of all isolates). *C. tropicalis (25.8%) and C. glabrata (24.7%) were the two most common non-albicans Candida species followed by *C. parapsilosis (8.1%), C. krusei (1.6%)*, and others (2.3%). When classified according to the sources, 273 (43.2%) of the isolates were from urine, 152 (24.1%) were from sputum, 51 (8.1%) were from blood, 49 (7.8%) were from wounds, and 107 (16.8%) were from other sites.
Susceptibilities to Amphotericin B and Fluconazole

The susceptibilities to amphotericin B are listed in Table 1. Only 3 of 632 isolates, one each of C. famata, C. krusei, and C. tropicalis, were resistant to amphotericin B. The MICs ranged from 0.06 to 2 µg/mL. The MIC of these isolates was 0.5 µg/mL and the MIC was 1 µg/mL. C. krusei were less susceptible to amphotericin B than were the other species, with MICs ranging from 0.5 to 2 µg/mL, a MIC50 of 1 µg/mL, and a MIC90 of 2 µg/mL.

The susceptibilities to fluconazole are listed in Table 2. A total of 53 (8.4%) and 45 (7.1%) isolates were resistant and susceptible-dose dependent. The MIC of these isolates was 1 µg/mL and the MIC was 1 µg/mL. C. krusei was less susceptible to amphotericin B than were the other species, with MICs ranging from 0.5 to 2 µg/mL, a MIC50 of 1 µg/mL, and a MIC90 of 2 µg/mL. C. tropicalis isolates were less susceptible to fluconazole than did C. albicans (4%) and other Candida species (0%). No C. krusei isolate was susceptible to fluconazole and the MIC50 of this species was 64 µg/mL. Approximately 78% and 79% of C. glabrata and C. tropicalis isolates, respectively, were susceptible to fluconazole. No C. parapsilosis isolate was resistant to fluconazole. Non-albicans Candida species had higher rates of resistance to fluconazole than did C. albicans (44 of 395 [11.2%] vs 9 of 237 [3.8%]; P = .002). Isolates from hospitals affiliated with tertiary-care medical centers had a higher rate of resistance to fluconazole than did those from regional and local hospitals (25 of 219 [11.4%] vs 27 of 410 [6.6%]; P = .05).

Species and Sources Accounting for Susceptibilities to Fluconazole

Candida species isolated from different sources had different susceptibilities to fluconazole (Table 3). All isolates from blood, with the exception of 4 C. tropicalis isolates and 1 C. krusei isolate, were susceptible to fluconazole (Table 3). Candida species isolated from different sources had different MICs (MIC50 and MIC90) to fluconazole (Table 4). The MIC50 of isolates from urine (4 µg/mL) was higher than that of isolates from other sources (0.5 to 1 µg/mL). The MIC90 of isolates from wounds (8 µg/mL) was lower than that of isolates from blood, sputum, and urine (16 to 32 µg/mL).

Co-resistance to Both Amphotericin B and Fluconazole

The trend of co-resistance to amphotericin B and fluconazole is outlined in Table 5. Fewer isolates with MICs to amphotericin B of 0.5 µg/mL or less were resistant to fluconazole compared with isolates with higher MICs (1 µg/mL or greater) to amphotericin B (30 of 462 vs 23 of 170; P = .007). Isolates with lower MICs to amphotericin B (0.5 µg/mL or less) had lower MIC50 and MIC90 to fluconazole than did isolates with higher MICs (1 µg/mL or greater) to amphotericin B (1 vs 2 µg/mL and 16 vs 64 µg/mL, respectively).

DISCUSSION

According to in vitro antifungal susceptibility testing, 0.5% and 8.4% of isolates were considered to be resistant to amphotericin B and fluconazole, respectively. The difference in rate of resistance between fluconazole and amphotericin B is a result of different mechanisms of antifungal activity, frequency of use, different molecular mechanisms of drug resistance, or all three. Two of these isolates resistant to amphotericin B (one C. krusei and one C. tropicalis) were also resistant to fluconazole. Although the rate of resistance to amphotericin B was low, there was a trend of co-resistance to amphotericin B and fluconazole.

Fungal infections caused by non-albicans Candida species have been increasing dramatically. C. krusei and C. glabrata have been considered intrinsically more resistant to fluconazole. In this study, no C. krusei isolate was susceptible to fluconazole, but C. glabrata was less resistant to fluconazole than in other studies (8% vs 15% or 45%). Overall, non-albicans Candida species had higher rates of resistance to fluconazole than did C. albicans. Most of the Candida species isolates from blood

### Table 4

<table>
<thead>
<tr>
<th>Source</th>
<th>C. albicans</th>
<th>C. tropicalis</th>
<th>C. glabrata</th>
<th>C. parapsilosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIC (µg/mL)</td>
<td>MIC50</td>
<td>MIC90</td>
<td>MIC50</td>
<td>MIC90</td>
</tr>
<tr>
<td>Blood</td>
<td>0.125-0.50</td>
<td>0.25</td>
<td>0.5-64</td>
<td>64</td>
</tr>
<tr>
<td>Sputum</td>
<td>0.125-512</td>
<td>0.25</td>
<td>8</td>
<td>25</td>
</tr>
<tr>
<td>Urine</td>
<td>0.125-64</td>
<td>0.25</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Wound</td>
<td>0.125-64</td>
<td>0.25</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration.

### Table 5

<table>
<thead>
<tr>
<th>Source</th>
<th>Amphotericin B</th>
<th>Fluconazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIC (µg/mL)</td>
<td>MIC50</td>
<td>MIC90</td>
</tr>
<tr>
<td>≤ 0.5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>&gt; 0.5</td>
<td>16</td>
<td>64</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration.
were susceptible to fluconazole. However, 4 (33.3%) of 12
C. tropicalis isolates from blood were resistant to flucona-
zole. The increasing rate of fluconazole resistance in C.
tropicalis (15%) is important because C. tropicalis is one of
the most commonly isolated non-albicans Candida
species.13,14 C. tropicalis develops drug resistance in the
presence of fluconazole much more rapidly than does C.
albicans.17,31 These findings may explain why C. tropicalis
(15%) had a higher rate of resistance to fluconazole than
did C. albicans (4%) and C. glabrata (8%).

Isolates of the same species from different sources
showed different susceptibilities to fluconazole. For example,
C. glabrata isolates from sputum had a higher rate of resistance
(15%) to fluconazole than those from blood (0%) or urine (7.5%),
whereas C. tropicalis isolates from blood had a higher rate of resistance (33.3%) to
fluconazole than those from sputum (13.9%) or urine
(17.8%). The fact that isolates from tertiary-care medical
centers had higher rates of resistance to fluconazole than
did those from regional and local hospitals needs to be
investigated further.

Different levels of susceptibility to fluconazole in the
same species from different sources complicates
diagnosis and treatment in the clinical setting. Hence,
accurate identification to the species level and susceptibil-
ity testing are crucial for clinical management, especially
for the emerging non-albicans Candida species that are
resistant to fluconazole.

REFERENCES

1. Pfaffer MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. SCOPE
Participant Group. National surveillance of nosocomial bloodstream
infection due to species of Candida other than Candida albicans: fre-
cquency of occurrence and antifungal susceptibility in the SCOPE

2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of noso-
Nosocomial Infections Surveillance System. J Infect Dis 1995;176:1247-
1251.

3. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular
trends in the epidemiology of nosocomial fungal infections at a teach-
ing hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol
1997;18:369-375.

4. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial can-
didiasis in a university hospital in Taiwan. J Formos Med Assoc

5. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular fac-
tors that contribute to antifungal drug resistance. Clin Microbiol Rev

6. Vandam Bossche H, Marichal P, Oddis FC. Molecular mechanisms of

7. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning
DW. High prevalence of antifungal resistance in Candida spp. from

and non-Candida fungal infections after liver transplantation.

9. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C. Mycoses

conazole resistance in Candida krusei. Antimicrob Agents Chemother

tant infections by Candida krusei and Candida glabrata in neutropenic

12. Akova M, Akalin HE, Uzun O, Gur D. Emergence of Candida krusei
infections after therapy of oropharyngeal candidiasis with fluconazole.

13. Prasad KN, Agarwal J, Dixit AK, Tiwari DP, Dhole TN, Ayyagari A.
Role of yeasts as nosocomial pathogens and their susceptibility to flu-

Candida species: SENTRY antimicrobial surveillance program in North
America and Latin America, 1997-1998. Antimicrob Agents Chemo-

15. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen

16. Graybill JR, Najvar LK, Holmberg JD, Luther ME. Fluconazole, D0870,
and fluconosine treatment of disseminated Candida tropicalis infec-

fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob

18. Baran J Jr, Klauer E, Barczak K, Khatib R. Trends in anti-
fungal susceptibility among Candida sp. urinary isolates from 1994 and

fungal susceptibility of 442 Candida isolates from blood and other nor-
mally sterile sites: results of a 2-year (1996 to 1998) multicenter sur-

due to a multiple-azole-resistant strain of Candida tropicalis. Clin Infect
Dis 1999;29:1583-1584.

Candida sp. isolates from HIV positive patients to several antifungal
drugs. Mycopathologia 2001;149:63-68.

22. Lo HJ, Ho AH, Ho M. Factors accounting for mid-identification of

23. National Committee for Clinical Laboratory Standards. Reference
Method for Broth Dilution Antifungal Susceptibility Testing of Yeats.
Wayne, PA: National Committee for Clinical Laboratory Standards;

24. Dean AG, Dean JA. Epi Info (6.04): A Word Processing, Database,
and Statistics Program for Epidemiology on Microcomputers. Atlanta:
Centers for Disease Control and Prevention; 1996.

25. Hitchcock CA. Cytochrome P-450-dependent 14 alpha-sterol demethy-
lase of Candida albicans and its interaction with azole antifungals.

clinical impact of antifungal drug resistance. Journal of Medical and

27. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S.
The epidemiology of hematogenous candidiasis caused by different

azole prophylaxis for fungal infections after marrow transplantation:
a prospective, randomized, double-blind study. J Infect Dis 1995;171:
1545-1552.

and flucytosine treatment of disseminated candidiasis. Antimicrob

for invasive fungal infections: analysis of safety and efficacy in 556

species in patients at a comprehensive cancer center. Antimicrob
Agents Chemother 2001;45:2129-2133.

32. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance
Chemother 1997;41:535-539.